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Case presentation
A 32-year-old man was admitted to the Instituto Nacional de Ia
Nutrición Salvador Zubirán for evaluation of chronic renal failure and
severe hypertension. The patient's history included frequent episodes
of pharyngitis during childhood. Five years before admission he noticed
left lumbar pain, malaise, and weakness. Two years later he developed
frontal headaches with blurred vision; blood pressure was 220/140 mm
Hg. Antihypertensive treatment was prescribed but the patient stopped
taking the medication when he began feeling better. Several weeks
before admission he developed 2 to 3 episodes of nausea and vomiting
per day, diarrhea, gingival bleeding, and epistaxis.
On admission, physical examination revealed a blood pressure of 220/
150 mm Hg; pulse, 84/mm; respirations, 14; temperature, 36.TC; and
weight, 68.9 kg. The optic fundi showed arteriolar narrowing, arteriove-
nous nicking, a few exudates, and small hemorrhages. The cardiac apex
was in the fifth intercostal space 10 cm left of the midsternal line. A
grade ll/IV systolic murmur, audible at the base, radiated to the left
sternal border. Peripheral pulses were normal and synchronous, and no
edema was present. There was no asterixis.
Laboratory findings revealed the following: hemoglobin, 6.7 g/dl;
white blood cell count, 8300/mm3; serum sodium, 132 mEq/liter;
potassium, 5.4 mEq/liter; chloride, 84 mEq/liter; BUN, 255 mg/dl;
creatinine, 24 mg/dl; calcium, 8.2 mg/dl; phosphorus, 15.2 mg/dl; total
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protein, 6.2 mg/dl; and albumin, 3.7 mg/dl. Urinalysis disclosed a pH of
7; protein, 7.3 g/liter; glucose, 3.2 g/liter; 3+ blood; and 5 to 10 red
blood cells and 5 to 7 white blood cells per high-power field.
Chest x-ray showed grade Il—Ill cardiac enlargement and a small
right pleural effusion. An electrocardiogram demonstrated left ventricu-
lar hypertrophy, and the echocardiogram showed both left ventricular
hypertrophy and dilatation with increased total ventricular mass. An
abdominal plain film revealed small kidneys bilaterally. The left mea-
sured 5.5 and the right 6.0 cm. Peritoneal dialysis for 15 days resulted in
a fall in BUN and serum creatinine to 68 and 9.6 mg/dl, respectively.
The patient was treated with hemodialysis twice weekly for the next 7
months while waiting for a kidney transplant. Average values for BUN
were 62 mg/dl; serum creatinine, 10 mg/dl; and hemoglobin, 7.3 g/dl.
Hypertension persisted despite high doses of antihypertensive medica-
tions, including 2.5 to 3.0 g of methyldopa, 160mg of furosemide, and 60
to 150mg of hydralazine, and constant ultrafiltration during hemodialy-
sis. Blood pressure varied from 180/100 to 240/150 mm Hg; average
blood pressure before and after hemodialysis was 186/117 and 177/108
mm Hg, respectively.
The patient was admitted to the metabolic ward for evaluation of
hypertension and was given a constant diet containing 40 mEq/day of
sodium and potassium, Antihypertensive medication was discontinued
5 days before the study was begun. Blood pressure was measured 5
times daily, body weight was measured twice daily, and plasma renin
activity and extracellular volume (measured as 131l iothalamate space)
were determined several times during the study (Fig. 1). During the
control period, mean blood pressure was 150 mm Hg. Extracellular
volume was elevated at 27% of body weight, as was plasma renin
activity at 14 ng/ml/hr. Ultrafiltration resulted in the following changes:
mean blood pressure fell slightly to 135 mm Hg; body weight fell by 3.5
kg; extracellular volume decreased to 20% of body weight; and plasma
renin activity increased to 35 ng/ml/hr. After administration of capto-
pril, 50 mg/day, a dramatic drop in the mean blood pressure from 150 to
80 mm Hg was observed; the plasma renin activity increased to 43 ng/
mi/br, and both the extracellular volume and body weight remained
unchanged. The addition of 75 mg/day of indomethacin increased the
mean blood pressure slightly to 100 mm Hg.
A kidney transplant from a living related donor was performed 7
months after the patient started hemodialysis. Blood pressure became
normal for only a few days after transplantation, rising progressively
over the following few months to 130 to 150 mm Hg diastolic in spite of
administration of methyldopa, hydralazine, and chlorthalidone.
Seven months after transplantation, proteinuria appeared, and the
serum creatinine level increased from 1.0 to 2.0 nig/dl. The patient was
readmitted to the metabolic ward for further evaluation. He received a
constant diet containing 10 mEq of sodium and 100 mEq of potassium.
Antihypertensive treatment was reduced to 60 mg of hydralazine and 50
mg of chlorthalidone daily; mean blood pressure varied between 140
and 155 mm Hg.
Glomerular filtration rate (measured with 1311 iothalamate infusion)
was 36.5 mI/mm. Administration of a single dose of captopril (50 mg)
reduced the blood pressure from 210/140 to 172/122 mm Hg in 90
minutes. Selective catheterization of renal veins was performed to
measure plasma renin activity. Results were the following: right kidney,
33.7; left kidney, 28.2; transplanted kidney, 7.2; vena cava below renal
veins, 9.7; and vena cava above renal veins, 26.0 ng/ml/hr.
The patient was treated with a total daily dose of 10mg of minoxidil,
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volume-responsive group. These observations suggested that
two types of hypertension existed in chronic renal failure; one
was "volume dependent" and the other "renin dependent" [15,
16]. As volume-dependent hypertension was by far the more
common condition (occurring in 90% to 95% of the patients) and
renin-dependent hypertension was uncommon, it was assumed
that volume expansion was the principal factor determining
hypertension in most patients with chronic renal failure and that
renin played a secondary role.
Nevertheless, hemodynamic studies from various labora-
tories demonstrated that uremic hypertensive patients have
increased peripheral resistance as compared to normotensive
patients with uremia or to normotensive healthy controls [8, 17,
_________
18—211. Cardiac index was similar in normotensive and hyper-
tensive patients with uremia but higher than in normals. This
elevation of cardiac index in uremia appeared to be related to
anemia because correction of the anemia decreased cardiac
index and produced further increments in blood pressure and
peripheral resistance [20].
15 These observations suggested that volume expansion could
increase blood pressure not only by raising cardiac output but
also by increasing peripheral resistance. The precise mecha-
nism by which volume expansion might increase peripheral
resistance remains uncertain. However, two possibilities have
been postulated in recent years: whole-body autoregulation and
increased reactivity of vascular and nervous cells. The latter
has recently been attributed to natriuretic hormone.
Whole-body autoregulation. The ability to maintain a rela-
tively constant blood flow rate in the presence of major changes
in perfusion pressure is termed autoregulation. This mechanism
is particularly efficient in kidney and brain but also operates in
many other organs and in the circulation as a whole. Ledingham
and Cohen [22, 23] and Guyton and coworkers [24—27] have
proposed that autoregulation in peripheral tissues is responsible
for elevating peripheral resistance and maintaining hyperten-
sion during chronic volume expansion. Accordingly, volume
expansion initially raises cardiac output and lowers peripheral
resistance, thereby producing increased perfusion to various
organs and tissues. These changes activate whole-body autore-
gulation leading to peripheral vasoconstriction with a gradual
lowering of cardiac output to normal. In the acute phase,
hypertension is maintained by high cardiac output, whereas in
the chronic phase, hypertension is maintained by increased
peripheral resistance. This sequence of events has been demon-
strated experimentally in dogs given an acute saline load after
they had been subjected to a two-thirds reduction in renal mass;
similar results were obtained by Coleman et al in anephric
patients [28] but not by others [29]. Volume expansion frequent-
ly coexists with the hypertension associated with chronic renal
failure; it therefore seems reasonable to assume that whole-
body autoregulation is at least partially responsible for the
peripheral vasoconstriction.
Increased reactivity of vascular cells. In 1952, Tobian and
Binion suggested that increased sodium chloride and water in
the arteriolar wall could be responsible for increased peripheral
resistance [30]. DeChamplain, Krakoff, and Axelrod more
recently demonstrated that sodium loading facilitates sympa-
thetic transmission and the release of norepinephrine from
adrenergic granules [311.
In the past few years, a natriuretic hormone has been
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Fig. 1. Effect of volume contraction and converting enzyme inhibition
on mean blood pressure and plasma renin activity.
120 mg of propranolol, and 80 mg of furosemide; he had an excellent
response. Blood pressure remains normal to the present time.
DR. JAIME HERRERA ACOSTA (Chief, Hypertension Clinic,
Department of Nephrology, Instituto Nacional de Nutrición
Salvador Zubirán, Mexico City, Mexico): Hypertension was the
first and most important clinical evidence of renal disease in this
patient; in fact, it was practically the only finding in the 3 years
before the patient developed the uremic syndrome. Elevated
blood pressure has been recognized for many years as a
frequent complication of chronic renal failure. In various series,
approximately 90% of patients entering dialysis programs are
hypertensive [1—5].
Hypertension in patients with chronic renal failure can be
produced by several mechanisms including volume expansion,
abnormalities in renin secretion, and hyperactivity of the auto-
nomic nervous system. A brief review of each of these mecha-
nisms is required for a complete understanding of the hyperten-
sion in the patient under discussion.
Role of volume expansion
Low-salt diets have been used as treatment of hypertension
in patients with renal disease for many years. Several recent
studies have shown a correlation between increased plasma
volume [6—9], extracellular volume [8, 10, 11], or exchangeable
sodium [7, 9, ll—14j and blood pressure in patients with renal
failure. Moreover, more than 20 years ago it was recognized
that regular hemodialysis was remarkably effective in control-
ling hypertension in patients with chronic renal failure [5].
Subsequently many studies confirmed this observation [1—4]. In
1969, Vertes et al studied 40 hypertensive patients with chronic
renal failure [151. In 35, blood pressure became normal when
"dry weight" was reached by fluid removal with dialysis; in the
remaining 5, blood pressure remained elevated. In these 5
patients, plasma renin activity was 10 times higher than in the
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implicated as a cause of increased vascular reactivity in vol-
ume-related hypertension [32, 33]. In chronic renal failure,
sodium homeostasis is maintained through various mecha-
nisms; among these is a factor thought to be a natriuretic
hormone [34—37]. This factor inhibits sodium reabsorption in
the distal tubule [38] and possibly contributes to the high
fractional sodium excretion characteristic of renal failure. Evi-
dence suggests that this factor is produced in the brain [32] in
response to volume expansion [39—4 1] and reaches its highest
levels in chronic renal failure [35, 36]. The factor presumably
acts by blocking the sodium-potassium ATPase pump in the
tubular cell [41], but it also can affect other transmembrane
transport processes and is thought to explain the increase in
intracellular sodium content of muscle [42], red cells [43—45],
and leukocytes [46, 47] in patients with uremia. These cells
show a decrease in sodium effiux and ouabain-sensitive ATPase
activity [44, 48] and, because this pump is coupled with the
sodium-calcium exchange system [49], its inhibition theoretical-
ly could increase intracellular calcium [50]. In muscle cells, the
change in intracellular electrolyte concentration raises basal
tone and contractility [501. Thus, in theory, increased contrac-
tility of smooth muscle of the arterioles, due in the final analysis
to an increase in natriuretic hormone, could explain the in-
creased peripheral resistance [50].
Changes in intracellular calcium could affect the nerve cell
similarly [49, 50], possibly by increasing its reactivity and
secretion of catecholamines, thereby providing another stimu-
lus to peripheral vasoconstriction. The observation that hemo-
dialysis reduces intracellular sodium [46—48] and lowers blood
pressure could be interpreted as evidence supporting this
theory.
Abnormalities of the renin-angiotensin system
Effects of bilateral nephrectomy. In 1960, chronic hemodialy-
sis made nephrectomy for control of blood pressure possible in
patients with malignant hypertension [16, 51]. The procedure
initially was restricted to patients with severe hypertension
uncontrollable by both dialysis and hypotensive drugs [16]. The
observation that nephrectomy was successful in some cases
suggested an important role for a renal pressor system. Proto-
cols for transplantation that included routine bilateral nephrec-
tomy allowed more detailed assessment of the kidney's role in
uremic hypertension. DelGreco performed bilateral nephrecto-
my in 145 hypertensive patients [17]. Hypertension improved
dramatically in 115 (79%) and remained unchanged in 30 (2 1%).
Hypertension was corrected in 74 of 79 patients with high
plasma renin activity and in only 13 of 29 with normal plasma
renin activity. (Renin was not measured in the other 17.) This
study demonstrated that the kidney can contribute to hyperten-
sion in as many as 80% of patients and that nephrectomy can
have an effect even in patients without hyperreninemia.
Kim, Onesti, and Swartz studied severely hypertensive pa-
tients in whom exchangeable sodium was unchanged before and
after bilateral nephrectomy [201. In these patients, the fall in
mean blood pressure from 147 to 93 mm Hg could be entirely
attributed to a decrease in peripheral resistance because cardiac
index remained constant. More recently, Bianchi et al studied 5
patients in whom hypertension was easily controlled by fluid
removal with dialysis and a low salt intake [52]. In these
patients, bilateral nephrectomy decreased diastolic blood pres-
sure from 106 to 80 mm Hg without producing any change in
extracellular volume or exchangeable sodium. This series of
studies clearly demonstrates an important role for the renal
pressor system not only in patients with uncontrollable hyper-
tension but also in those who respond to volume contraction.
Integrity of the renin-angiotensin system in chronic renal
disease: Role of circulating plasma renin activity in the hyper-
tension of chronic renal ftuilure. The renin-angiotensin system
apparently preserves its functional integrity in kidney failure
even in the most advanced stages [53]. Volume contraction
induced by diuretics or dialysis consistently stimulates renin
secretion [53—59]. Leenen et al showed that plasma renin
activity and aldosterone levels increase with a low-salt diet and
decrease with a high salt intake in patients with polycystic
kidney disease [60]. The normal response of plasma renin
activity to orthostasis also is well preserved [53, 60, 61]. In our
group of 9 patients with moderate chronic renal failure, plasma
renin activity increased 150% (to 4.6—11.5 ng/ml/hr) with a low-
salt diet and decreased 56% (to 2.7—4.2 ng/ml/hr) with a high-
salt diet.
Mean values of plasma renin activity in the hypertensive
patients with chronic renal failure are normal or slightly elevat-
ed, but the variation from patient to patient is greater than that
in normal individuals; in almost every series, values for plasma
renin activity are as low as 0.1 and as high as 35 ng/ml!hr [6, 7,
9, 53, 54, 62—65]. Using 5 ng!ml/hr as the maximal normal value
for patients on a salt-free diet, different series reported the
frequency of hyperreninemia to be approximately 30% in 233
patients with chronic renal failure [53—55, 62—65]. Our own
laboratory found hyperreninemia in 3 of 9 hypertensive patients
with mild to moderate chronic renal failure (GFR, 11—49 ml!
mm) and in 10 of 13 hypertensive patients on maintenance
hemodialysis. More recently, Fadem and Lifschitz showed that
specific blocking of angiotensin II by saralasin was associated
with increased renin secretion [62]. These data confirm the
integrity of the renin-angiotensin system in renal disease at all
stages of disordered renal function.
In the patient under discussion today, severe uncontrollable
hypertension was associated with hyperreninemia (14—35 ng/ml/
hr). This finding is in accord with many series in which most of
the patients with uncontrollable hypertension have elevated
values of plasma renin activity [15, 16, 55, 64], whereas milder
hypertension is associated with normal or low values. The
cause of renal disease was not established by renal biopsy in our
patients, but their clinical course, severity of hypertension, and
lack of significant proteinuria and edema are compatible with
nephrosclerosis.
The relationship among hypertension, renin secretion, and
the cause of renal disease was studied by Weidmann and
Maxwell [54]. Nephrosclerosis was associated with high plasma
renin activity and controllable hypertension in almost every
case; in patients with glomerular lesions, 66% had controllable
hypertension, yet only 50% had hyperreninemia. By contrast,
approximately 75% of patients with tubulointerstitial lesions
had normal or low plasma renin activity and normal blood
pressure.
Relationship between renin and volume in the hypertension
of chronic renalfailure. In 1970, Warren and Ferris studied the
response of plasma renin activity to volume changes in hyper-
tensive patients with chronic renal failure [66]. They established
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Fig. 2. Relationship between mean blood pressure and the
product of plasma renin activity and extracellular volume.
that renin secretion was inappropriate for the volume status
because saline infusion failed to suppress renin, whereas in
control subjects, a smaller fluid load completely inhibited renin
secretion. This evidence was probably the first suggesting an
abnormal relationship between renin and fluid volume. In 1973,
Davies and coworkers measured blood pressure, exchangeable
sodium, and plasma renin activity in a group of normotensive
controls and hypertensive patients with chronic renal failure
[111. Highly significant inverse correlations were found be-
tween exchangeable sodium and plasma renin and angiotensin
II levels in normotensive subjects with or without chronic renal
failure. In 7 of 9 untreated hypertensive patients with chronic
renal failure, however, an abnormal relationship was apparent;
for similar values of exchangeable sodium, the angiotensin II
level was considerably higher. Thus, apparently normal values
of plasma renin and angiotensin II were actually elevated when
considered in relation to the patient's sodium and volume
status.
In 1976, Weidmann and coworkers demonstrated an inverse
correlation between plasma renin activity and exchangeable
sodium for both normotensive and hypertensive patients with
chronic renal failure. For any given level of exchangeable
sodium, however, plasma renin activity was more than twice as
high in hypertensive patients as in normotensive individuals [7].
Blood pressure correlated significantly with the sodium-renin
product (exchangeable sodium x log plasma renin activity) and,
to a greater extent, with the product of sodium, renin, and
duration of previous hypertension.
We obtained similar results in our laboratory with 16 patients
being treated with hemodialysis. Most of the hypertensive
patients, as illustrated by today's case, had increased extracel-
lular volume [measured as the space of 13h1 iothalamate (26.9
1.8% of body weight)] as well as increased plasma renin activity
values (>5 ng/ml/hr); these findings indicated an abnormal
relationship between volume and renin. A significant correla-
• tion was found between blood pressure and both extracellular
volume (r = 0.69) and plasma renin activity (r = 0.69) , but the
significance increased considerably (r = 0.79) when blood
pressure was related to the product of plasma renin activity and
extracellular volume. These data are shown in Figure 2.
An important concept derived from these studies is that in
end-stage renal failure there is a resetting of the sodium-
volume-renin feedback mechanism. Evidence in favor of this
hypothesis has been provided by most studies [7, 11, 66, 671 but
not by all [61. The factors responsible for the resetting remain to
be defined, but it is possible, as suggested by Weidmann et al
[7], that distortion of renal architecture by disease can produce
renal ischemia and stimulate inappropriate renin release at any
given state of extracellular volume. At least one other possibili-
ty might explain renin release: an increase in sympathetic
nervous system activity.
Effect of renin-angiotensin system blockade. The angiotensin
antagonist, saralasin, has been used to diagnose renin-depen-
dent hypertension [68, 69]. Recently Fadem and Lifschitz used
500 saralasin to evaluate the participation of the renin-angiotensin
system in hypertensive patients on chronic hemodialysis [621.
Infusion of saralasin the day after dialysis decreased blood
pressure in only one-third of 27 patients studied. In these,
plasma renin activity was 61 ng!ml/3 hours and rose to 96 ng/ml
after saralasin was administered. In the remaining patients
whose blood pressure was unaffected by saralasin administra-
tion, plasma renin activity was 15 ng/ml/3 hours both before and
after they received the drug. In a smaller group of patients,
however, Mimran et al found a depressor response to saralasin
in 6 of 7 patients before and after hemodialysis [70]. Saralasin
also was used by Brod et al in 11 hypertensive patients with
chronic renal disease who had not yet developed uremia [63].
Vasodepressor response was observed in only one of these
patients, who was found to have a high level of plasma renin
activity. The other 10 patients had plasma renin activity values
lower than 2 nglml/hr, and none of these patients responded.
The results obtained with the angiotensin antagonist suggest
that renin does contribute to hypertension in some patients with
chronic renal disease, usually those with high plasma renin
activity. These results contrast with other studies suggesting
that renin contributes to blood pressure elevation in the great
majority of cases even when plasma renin activity is normal [7,
11, 66, 67]. The explanation for this discrepancy is uncertain,
but it is possible that saralasin has angiotensin-like activity
when circulating renin is low (particularly in the sodium-loaded
state) and in such circumstances it actually can raise blood
pressure [71—73]. In the series of Fadem and Lifschitz, for
example, a small rise in blood pressure was observed during
saralasin infusion in some patients, some of whom had normal
plasma renin values [62]. It is possible therefore that the
agonistic action of saralasin results in an underestimation of
renin's contribution, because the hypotensive effect of saralasin
would occur only in patients with hyperreninemia and not in
patients in whom the renin level is apparently normal (but
elevated when considered relative to sodium status).
Another means of evaluating the contribution of the renin-
angiotensin system to control of blood pressure has been the
use of converting enzyme inhibitors. Converting enzyme inhibi-
tors are effective in reducing blood pressure in almost all
patients with chronic renal failure. In the patient under discus-
•
•
•
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Control Sodium Captopril
depletion
Fig. 3. Effect of sodium depletion and converting enzyme inhibition on
mean blood pressure and plasma renin activity in patients with end-
stage chronic renal failure on hemodialysis (closed circles, closed bars)
and in patients with moderate chronic renal failure (open circles, open
bars).
sion today, blood pressure was reduced to normal levels with
small oral doses of the converting enzyme inhibitor, captopril.
This result, which demonstrates that hypertension was renin
mediated, was not surprising because plasma renin activity
values were elevated in this patient even though extracellular
volume was increased.
To evaluate the relative participation of volume expansion
and inappropriate renin secretion in the hypertension of chronic
renal failure, we compared the effect of volume contraction
with that of converting enzyme inhibition. The first study group
consisted of 7 patients being treated with hemodialysis; the
second group consisted of 9 patients with moderate chronic
renal failure. After a control period, volume depletion was
induced with hemodialysis and ultrafiltration in the patients
with end-stage chronic renal failure; the extracellular volume
was reduced to 20% of body weight. In the patients with
moderate chronic renal failure, volume depletion was produced
by a low-salt diet (10 mEq) and two doses of furosemide (40 mg
each). After induction of volume contraction, captopril was
given at doses of 50 to 150 mg/day to both groups. Results are
shown in Figure 3. The patients with end-stage chronic renal
failure had higher values of blood pressure and plasma renin
activity than did those with moderate chronic renal failure.
Volume depletion did not change blood pressure significantly in
either group. Plasma renin activity increased in both, from an
average of 15 to 18 ng/ml/hr in patients with end-stage chronic
renal failure, and from an average of 4 to 11 ng/ml/hr in patients
with moderate chronic renal failure. Captopril reduced mean
blood pressure to the normal range in both groups, increasing
plasma renin activity further to 30 ng/ml/hr in patients with end-
stage chronic renal failure and to 24 ng/ml/hr in patients with
moderate chronic renal failure. In 2 patients with end-stage
chronic renal failure who had normal plasma renin activity
values before receiving captopril, the fall in mean blood pres-
sure was 21 and 37 mm Hg. Two patients with moderate chronic
renal failure also had normal plasma renin activity before
captopril administration (5.6 and 5.8 ng/mllhr), yet they too
responded to the drug. The fall in mean blood pressure in these
individuals was 11 and 21 mm Hg.
These results indicate that blocking the renin-angiotensin
system has a far more potent antihypertensive effect than does
correcting volume expansion. This remarkable antihyperten-
sive effect of converting enzyme inhibitors in the hypertension
of chronic renal failure has been described previously. Brunner
et a! in 1980 reported that captopril alone or captopril combined
with diuretics lowered blood pressure to normal in a large
proportion of patients with chronic renal failure who also had
hypertension [74—761.
These observations suggest that renin has a major role in the
hypertension of chronic renal failure in almost every case. But
we should be cautious about this interpretation, particularly
because some aspects of the mechanism of action of converting
enzyme inhibitors are still a matter of considerable controversy
175, 77—80]. In forms of hypertension associated with activation
of the renin-angiotensin system, including renovascular hyper-
tension in the human [75] and the "two kidney, one clip"
Goldblatt model in the rat [81, 82], the antihypertensive effect is
thought to be entirely due to suppression of the renin-angioten-
sin system. In conditions associated with normal or low renin,
however, the hypotensive effect has been attributed to other
mechanisms. One theory explaining the hypotensive effect of
converting enzyme inhibitors in these latter cases postulates
that converting enzyme inhibitors increase bradykinin activity.
Since converting enzyme is identical to kininase II, the enzyme
that normally degrades bradykinin, suppression of converting
enzyme theoretically could increase bradykinin [77, 78]. Unfor-
tunately, direct measurements of bradykinin and concomitant
inhibition of its synthesis with aprotinin (Trasylol) have given
conflicting results [77, 79, 83—851. Thus the role of bradykinin in
the hypotensive effect of captopril remains to be defined.
The proposal that the effect of captopril might be related to an
increased release of vasodepressor prostaglandins is also a
matter of considerable controversy [77—80]. In the patient under
discussion, inhibition of prostaglandin synthesis with indometh-
acm during captopril therapy did not abolish the hypotensive
effect of captopril. We saw the same effect in 4 other patients
who received both drugs; addition of indomethacin decreased
mean blood pressure further, from 100 to 95 mm Hg.
Several earlier studies demonstrated that inhibition of prosta-
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Fig. 4. Plasma renin activity in samples obtained by selective catheter-
ization of renal veins of host and transplanted kidneys and vena cava
below renal veins. Results were obtained from 11 patients with hyper-
reninemia and posttransplant hypertension.
glandin synthesis does not prevent lowering of blood pressure
with captopril [77, 791; however, inhibition of pro staglandin
synthesis with 100 mg of indomethacin prevented both a rise in
prostaglandins and the depressor response [80].
Finally, it has been proposed that captopril lowers blood
pressure in hypertension associated with normal or low plasma
renin activity by inhibiting the renin-angiotensin system in
arterial wall tissue [77, 78, 86]. Arterial wall tissue in several
species, including humans, contains all the components neces-
sary for local generation of angiotensin II [87]. Local angioten-
sin II formation responds to classical stimuli and is not always
related to circulating plasma renin activity [88]. Thus inhibition
of arterial wall angiotensin II might explain the captopril-
induced reduction of blood pressure even when the plasma
renin activity is low. Other angiotensin II antagonists such as
saralasin may not be effective because their relatively large
molecular size prevents them from penetrating the arterial wall
[86].
Posttransplantation hypertension. In the patient under dis-
cussion today, hypertension persisted after he received a suc-
cessful kidney allograft. The known causes of posttransplanta-
tion hypertension include acute or chronic rejection, stenosis of
the transplanted renal artery, presence of the patient's diseased
kidneys, high doses of steroid therapy, and hypercalcemia [89—
931.
This patient is particularly interesting because he illustrates
the mechanism whereby host kidneys induce posttransplanta-
tion hypertension. We studied 19 patients who had undergone
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Fig. 5. Effect of captopril and sodium depletion on mean blood
pressure, plasma renin activity, and urinary aldosterone in 4 patients
with posttransplant hypertension associated with renin hypersecretion
by host kidneys.
renal transplantation; in 12, hypertension was associated with
high values of circulating plasma renin activity [89]. Seven
normotensive patients had normal or slightly elevated renin
values. Renal vein catheterization of both host and transplanted
kidneys disclosed higher plasma renin activity in host than in
transplanted kidneys in the 11 patients studied (Fig. 4). Thus, as
reported by others, hyperreninemia in these patients is pro-
duced by the native kidneys [91—931. This assertion is corrobo-
rated by the observation that nephrectomy corrects both hyper-
reninemia and hypertension, as it did in 2 of our patients.
Recently Linas et al used saralasin to examine the role of
renin in 12 patients with posttransplantation hypertension [931.
In all patients who had retained their own diseased kidneys, a
depressor response occurred after sodium restriction. We have
evaluated the effect of captopril in 4 patients with posttrans-
plantation hypertension and hypersecretion of renin from their
diseased kidneys. During normal sodium intake, the administra-
tion of 150 to 450 mg/day of captopril decreased mean blood
pressure from 134 5 to 106 2.5 mm Hg. During sodium
restriction, captopril reduced the mean blood pressure further,
to 93 2 mm Hg (Fig. 5). These observations demonstrate that
in some patients, diseased kidneys continue to secrete exces-
sive quantities of renin after successful renal transplantation,
thus contributing to posttransplant hypertension. These find-
ings also support the existence of an abnormal volume-renin
feedback mechanism in end-stage renal disease.
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In the patient under consideration today, posttransplant
hypertension probably was related to several factors. Even
though plasma renin activity was higher in the host kidneys than
in the transplanted kidney (and renal secretion was probably
suppressed in the latter), the response to captopril was neither
as striking as it had been when the patient had been on
hemodialysis (Fig. 1), nor as remarkable as that observed in the
other 4 patients (Fig. 5). In fact, this patient had evidence of
chronic rejection, as indicated by proteinuria and a glomerular
filtration rate of 36 mi/mm. Thus we reasonably can conclude
that after transplantation, hypertension in this patient was
produced both by chronic rejection and abnormal secretion of
renin by the host kidneys.
Influence of the sympathetic nervous system
Hypertension in chronic renal failure has been widely studied
with regard to sodium homeostasis and the renin-angiotensin
system, but little is known about the role of the autonomic
nervous system. Recently abnormal baroreflex sensitivity and
impaired autonomic nervous system activity have been de-
scribed in chronic renal disease [94—96]. Almost all patients
with chronic renal failure have diminished baroreflex sensitiv-
ity. Resetting the blood pressure level at which the baroreflex is
suppressed allows the adrenergic outflow to continue at a
higher blood pressure. Several factors can contribute to this
derangement; the most important ones are uremic neuropathy,
chronic hypertension, and age.
Plasma catecholamines in patients with chronic renal failure
are quite variable. Brecht, Ernst, and Koch found similar
plasma norepinephrine concentrations in normotensive and
hypertensive patients but, in both groups, values were higher
than in healthy control subjects studied under similar conditions
[971. By contrast, Atuk, Westervelt, and Peach reported higher
total catecholamine concentrations in hypertensive than in
normotensive patients with chronic renal failure [98]. More
recently McGrath, Ledingham, and Benedict noted elevated
plasma epinephrine levels in hypertensive patients on chronic
hemodialysis; norepinephrine levels were normal in normoten-
sive and hypertensive patients [991. Other studies have revealed
normal or low values of both norepinephrine and epinephrine as
well as other markers of autonomic activity, such as the enzyme
dopamine beta hydroxylase [61, 100—102]. It is important to
point out that many of the differences probably are due to
technical factors, and more studies are needed to assess plasma
catecholamine levels.
McGrath and coworkers induced total autonomic blockade
with atropine, propranolol, guanethidine, and phentolamine in
patients on hemodialysis and showed that this regimen was
associated with a marked fall in blood pressure in hypertensive
patients, even those who were volume expanded [21]. The fall
in blood pressure was due to a decrease in peripheral resistance
and could not be explained by any change in activity of the
renin-angiotensin system. Even though this manipulation sug-
gests that autonomic factors participate in raising total peripher-
al resistance, it does not rule out the contribution of other
factors. All these data make the participation of the autonomic
nervous system in the hypertension of chronic renal failure
likely, but the precise role of this system has not yet been
defined.
Questions and answers
DR. JEROME P. KASSIRER: You have convincingly argued that
we have underestimated the role of the renin-angiotensin sys-
tem in the hypertension of parenchymal renal disease. How do
you put into perspective the recent limited experience with
hypertension in patients treated with continuous ambulatory
peritoneal dialysis (CAPD)? Blood pressure in the patients who
have been treated with this modality seems to be much better
controlled than it is either with intermittent hemodialysis or
intermittent peritoneal dialysis. Do you have the same experi-
ence and, if so, how do you explain this observation?
DR. HERRERA ACOSTA: Yes, in our experience and that of
others in Mexico City, patients treated with CAPD seem to
have hypertension less often. I assume that this form of
treatment produces a greater degree of volume depletion and
thus lowers blood pressure even if renin is high. This response
may be analogous to that occurring in patients with renovascu-
lar hypertension who take diuretics.
DR. JosE MA. CHAVEZ DE LOS Rios (Chief, Metabolic Unit,
Centro Medico La Raza, Instituto Mexicano del Seguro Social,
Mexico City): I am not convinced that one can completely rule
out volume expansion as a cause of hypertension in today's
patient. During the metabolic study, reducing extracellular
volume with ultrafiltration reduced blood pressure transiently;
however, there was a simultaneous increase in plasma renin
activity that could have prevented a greater fall in mean blood
pressure. Also, during the last part of the study when indometh-
acm was given, blood pressure increased parallel with an
increase in body weight.
DR. HERRERA ACOSTA: Under all circumstances, of course,
the volume status of a patient contributes to the level of blood
pressure that is maintained. If one volume-depletes a patient
sufficiently, there will always be a fall in blood pressure.
However, the observations in this patient demonstrate that the
main factor contributing to hypertension is an alteration in the
renin-volume feedback. Renin values were elevated in the
presence of volume expansion and increased further when
volume was reduced to normal. Furthermore, inhibiting the
converting enzyme produced a profound drop in blood pressure
to normal, indicating a predominant role for the renin-angioten-
sin system.
DR. FRANCISCO Rufz MAZA (Chief of Nephrology, Hospital
Español, Mexico City): Do you recommend that we perform
"renin profiling" in all hypertensive patients who are being
treated with dialysis? I am not convinced that this would be a
profitable approach. Inmost of these patients, hypertension can
be controlled by dialysis alone.
DR. HERRERA ACOSTA: I do not recommend extensive renin
profiling in every hypertensive patient with uremia. The studies
I described in my discussion were done for research purposes to
evaluate the role of renin and volume. However, by determin-
ing the hypotensive response to specific inhibitors of the renin-
angiotensin system, one can derive a rough estimate of the
contribution of renin to hypertension in a given patient. Be-
cause this simple test can be carried out using an oral agent, it is
a pragmatic clinical test that can provide as much useful
information as renin determination can.
DR. Rufz MAZA: Do you have specific recommendations
regarding the comparative usefulness of sequential ultrafiltra-
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tion, hemoperfusion, or a combination of these techniques with
regular hemodialysis? Do you think there is an optimal, specific
dialytic program that one should apply in moderately to severe-
ly hypertensive uremic patients on dialysis? Would you also
comment on the combination of new potent antihypertensive
drugs such as beta blockers, captopril, and minoxidil and these
dialytic procedures?
DR. HERRERA ACOSTA: At present, we can control the blood
pressure of most patients by adjusting the rate of ultrafiltration
during hemodialysis to maintain these patients close to their
"dry weight" and, when necessary, by adding one or more of
the antihypertensive drugs you mentioned.
DR. ALEJANDRO TREV1O (Chi ef of Nephrology Department,
Centro Medico La Raza, Instituto Mexicano del Seguro Social,
Mexico City): I noticed that you did not use beta blockers in the
patient you discussed. Have you any experience with them?
DR. HERRERA ACOSTA: Beta blockers have proved effective
in treating hypertension associated with chronic renal failure.
We have had very good results both with propranolol and
nadolol. Studies in patients with chronic renal failure conducted
in our laboratory demonstrated that elimination of these agents
is quite prolonged in advanced renal failure; the half-life can be
as long as 96 hours in patients on hemodialysis. Therefore, one
should adjust the dose of the drug to the level of renal function
in individual patients.
DR. KASSIRER: Would anyone like to comment on the role of
removing patients' diseased kidneys in the treatment of
hypertension?
DR. MANUEL TORRES ZAMORA (Chief of Nephrology, Centro
Medico Nacional, Instituto Mexicano del Seguro Social, Méxi-
co City): In the General Hospital of the Centro Medico Na-
cional in Mexico City, nephrectomy was performed in 16
patients who received renal transplants. In 10, nephrectomy
was done before the transplant; in 6, after. Fourteen became
normotensive and remained so from 6 months to 6 years after
transplantation. These results are similar to those reported in
the literature. They imply that renin release by host kidneys is
important in posttransplantation hypertension as Dr. Herrera
Acosta has stressed. In one of our patients whose blood
pressure was restored to normal by nephrectomy, hypertension
recurred after transplantation. The patient again became nor-
motensive after surgical correction of renal artery stenosis of
the transplanted kidney. In this patient, hypertension probably
also was related to increased renin release. Of course, this
phenomenon has been described by others.
With the exception of patients who develop renal artery
stenosis in the transplanted kidney, it is my view that posttrans-
plantation hypertension probably is due to volume expansion as
well as to increased renin release. In such patients I view the
hypertension as similar to that found in end-stage renal disease:
a disorder caused by both renin release and volume expansion.
DR. HERRERA ACOSTA: We think that the main mechanism by
which host kidneys induce posttransplantation hypertension is
renin hypersecretion. I agree with you, however, that other
factors probably are involved. The role of volume expansion as
such is difficult to assess, particularly if renal function is normal
in the patient with a transplanted kidney. Under those condi-
tions one would expect that the rise in blood pressure produced
by excess angiotensin II would induce a pressure natriuresis in
the grafted kidney, thereby preventing volume expansion even
if aldosterone levels were elevated. If this mechanism were
operative, hypertension presumably would not occur. It seems
reasonable therefore to argue that some element of volume
expansion must be present for hypertension to develop. If
volume expansion does occur, however, it is probably very
slight. We have measured extracellular volume as 'I iothala-
mate space in a few patients, including the one we have
discussed today, and it was normal. However, one must bear in
mind that these methods are subject to considerable error and
only detect large changes.
DR. KASSIRER: Before the new antihypertensive drugs were
available, nephrologists had to choose either the consequences
of bilateral nephrectomy or those of unrelieved hypertension.
The risks of both of those choices was very high. Today we
trade off the risks and benefits of nephrectomy for the risks and
benefits of drug therapy. When weighing these elements today,
how often does nephrectomy win out as the optimal approach?
DR. HERRERA AcosTA: Certainly we do far fewer nephrecto-
mies for control of hypertension today. In our series of 130
transplants, we have had to resort to pretransplant nephrecto-
my to control hypertension in only one patient. As you have
mentioned, the availability of potent antihypertensive drugs and
converting enzyme inhibitors makes it possible for us to control
almost all instances of severe hypertension and, in our experi-
ence, the side effects of such therapy usually are not
prohibitive.
DR. TORRES ZAMORA: Our experience is consistent with
yours.
DR. CHAVEZ DE LOS Rfos: Have you noticed any deteriora-
tion of renal function during captopril therapy in your patients
with chronic renal failure? We have encountered this complica-
tion when treating hypertension with beta blockers, and the
literature contains similar reports.
DR. HERRERA ACOSTA: We have studied the effects of
captopril on renal function in several clinical conditions. One of
them was in groups of patients with essential hypertension
receiving low and normal sodium intakes. Patients ingesting a
low-salt diet who received captopril had a much lower blood
pressure, which was associated with a 20% drop in GFR;
patients ingesting a normal sodium diet who were given capto-
pril experienced no change in either blood pressure or GFR.
Renal plasma flow increased slightly in patients on both diets.
In a group of patients with moderate chronic renal failure who
were receiving a low-salt diet, captopril produced an important
drop in mean blood pressure, from 116 to 98 mm Hg, but GFR
did not change significantly.
DR. ARTURO DIB KuRI (Transplantation Unit, Department of
Surgery, Instituto Nacional de la Nutrición Salvador Zubirdn,
Mexico City): It seems to me that hypertension in this patient
was due mainly to the hyperreninemia from his own kidneys. I
don't think we can ascribe this patient's hypertension to
rejection. First, hypertension appeared a few days after trans-
plantation, and second, creatinine values returned to normal
after hypertension was controlled with captopril. The patient
did not receive treatment for rejection. Do you think the severe
hypertension produced this degree of damage to the transplant-
ed kidney in only a few months?
DR. HERRERA ACOSTA: The presence of significant protein-
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uria, associated with a small rise in serum creatinine and a
reduction of GFR to 36 mi/mm suggests to me that renal damage
was produced by chronic rejection, because hypertension in
itself usually does not produce proteinuria of this magnitude.
Although hyperreninemia was well documented in this patient,
the response to captopril was not as striking as it had been when
he was on hemodialysis, Therefore we believe that other factors
probably were contributing to his hypertension, including rejec-
tion, volume expansion, and steroids.
Reprint requests to Dr. J, Herrera Acosta, Chief, Hypertension
Clinic, Instituto Nacional de Nutrición Salvador Zubirdn, Av. San
Fernando y Viaducto Tlalpan, Mexico 22, DF
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